tyloxapol


Also found in: Wikipedia.

tyloxapol

 [ti-loks´ah-pol]
a nonionic liquid polymer used as a surfactant to aid liquefaction and removal of mucopurulent bronchopulmonary secretions; administered by inhalation.

ty·lox·a·pol

(tī-loks'ă-pol),
A detergent and mucolytic agent used as an aerosol to liquify sputum.

tyloxapol

/ty·lox·a·pol/ (ti-loks´ah-pol) a nonionic liquid polymer used as a surfactant to aid liquefaction and removal of mucopurulent bronchopulmonary secretions, administered by inhalation.

tyloxapol

[tīlok′səpôl]
an ocular lubricant used to lubricate, clean, and wet artificial eyes to improve wearing comfort; it also has a detergent action that is used to help break up mucus.

tyloxapol

a nonionic liquid polymer used as a surfactant to aid liquefaction and removal of mucopurulent bronchopulmonary secretions; administered by inhalation.
References in periodicals archive ?
Tenders are invited for Supply of Drop Brinzlamine 10 Mg Activate Inactivated Benzalkonium Chloride Ep 10 Mg, Mannitol Carbopol 974 P, Tyloxapol, Disodium Acetate, Sodium Chloride, Sodium Hydroxide For Eye In 5 Ml Ph.
Although there are only a limited number of such products, one example is Blink-N-Clean (Abbott Medical Optics Inc, Santa Ana, California, USA), which contains the surfactant Tyloxapol and edetate disodium as a chelating agent.
One of the first available protein-free, artificial surfactant preparations was Exosurf, or colfosceril palmitate plus cetyl alcohol and tyloxapol.
Although the patients received nebulised salbutamol and tyloxapol (a mucolytic agent) at four-hour intervals, insufficient humidification of the jet stream contributed to the formation of extremely tenacious secretions.
Preclinical tests have shown that tyloxapol, the active ingredient in SuperVent(TM) Aerosol Solution, is a potent anti-oxidant, has anti-inflammatory activity through inhibition of NF-(kappa)B, and reduces the viscosity of sputum.
Discovery is also developing SuperVent(TM), its aerosolized formulation of tyloxapol for cystic fibrosis (CF) and has recently released positive results from its Phase 2A clinical trial in CF.
Preclinical tests have shown that tyloxapol, the active ingredient in SuperVent(TM) Aerosol Solution, is a potent anti-oxidant that has anti-inflammatory activity through inhibition of NF-(kappa)B, and reduces the viscosity of sputum.
In addition to Surfaxin(TM), Discovery is developing SuperVent(TM), its aerolosized formulation of tyloxapol for cystic fibrosis.